#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	17150	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2425	870.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1622	1622	C	1064	C,A	1062,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28478	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3912	906.9	0	.	n	.	0	T695C	SNP	695	695	T	1255	1255	C	1008	C,T,G	1006,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28478	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3912	906.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1897	1897	A	1144	A,C	1143,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28478	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3912	906.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2531	2531	C	979	C,T	977,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28478	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3912	906.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2605	2605	A	893	A	892	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28478	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3912	906.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3157	3157	C	960	C,T	958,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2264	folP	852	852	100.0	folP.l15.c4.ctg.1	1962	144.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1254	1256	AGC	204;205;202	A,C;G;C	203,1;205;202	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5490	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3899	175.9	1	SNP	p	S91F	0	.	.	271	273	TCC	805	807	TCC	218;218;218	T;C;C	218;218;218	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5490	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3899	175.9	1	SNP	p	D95N	0	.	.	283	285	GAC	817	819	GAC	225;226;228	G;A;C,G	225;226;227,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5490	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3899	175.9	1	SNP	p	D95G	0	.	.	283	285	GAC	817	819	GAC	225;226;228	G;A;C,G	225;226;227,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1944	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1791	135.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	761	763	ACC	175;175;173	A;C;C	175;175;173	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1944	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1791	135.4	0	.	p	.	0	R44H	NONSYN	130	132	CGC	776	778	CAC	168;167;169	C;A;C,T	168;167;168,1	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1944	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1791	135.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	959	961	CAC	279;279;280	C;A;C,A	279;279;279,1	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1944	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1791	135.4	1	SNP	p	G45D	0	.	.	133	135	GGC	779	781	GGC	173;176;178	G;G;C	172;175;177	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1110	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1496	92.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5310	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3546	187.1	1	SNP	p	D86N	0	.	.	256	258	GAC	858	860	GAC	240;245;246	G;A,G;C	240;243,2;246	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5310	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3546	187.1	1	SNP	p	S87I	0	.	.	259	261	AGT	861	863	AGT	245;244;244	A,C;G;T	244,1;244;244	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5310	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3546	187.1	1	SNP	p	S87R	0	.	.	259	261	AGT	861	863	AGT	245;244;244	A,C;G;T	244,1;244;244	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5310	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3546	187.1	1	SNP	p	S87W	0	.	.	259	261	AGT	861	863	AGT	245;244;244	A,C;G;T	244,1;244;244	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5310	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3546	187.1	1	SNP	p	S88P	0	.	.	262	264	TCC	864	866	TCC	244;244;242	T,G;C,T;C	243,1;242,2;242	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4544	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3225	175.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1853	1855	GGC	237;233;231	G;G;C	237;233;231	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1558	1560	GCA	251;252;253	G;C;A	251;252;253	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1561	1563	ATC	255;254;255	A;T,A;C,G	255;253,1;254,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1573	1575	GTG	261;262;263	G;T;G	261;262;263	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1573	1575	GTG	261;262;263	G;T;G	261;262;263	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2077	2079	ACC	230;233;231	A;C;C,A	230;233;230,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2131	2133	GCG	209;212;210	G;C;G,T	209;212;209,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2131	2133	GCG	209;212;210	G;C;G,T	209;212;209,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2254	2256	GGC	232;233;234	G;G,A;C,A	232;232,1;233,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2263	2265	GGC	234;236;237	G,T;G,T;C	233,1;235,1;237	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4230	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2926	180.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2281	2283	CCG	233;232;232	C;C;G	233;232;232	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6060	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3618	209.1	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1838	1840	CTG	261;264;262	C,G;T,C;G,A	260,1;262,2;261,1	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2632	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2221	147.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	750	750	C	194	C	194	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	672	674	GGA	264;268;270	G;G,A;A,T,G	263;266,1;268,1,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	0	.	p	.	0	G129S	NONSYN	385	387	GGC	915	917	AGC	223;221;221	A;G;C,T	223;221;220,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	0	.	p	.	0	F135L	NONSYN	403	405	TTT	933	935	CTT	227;227;227	C;T;T,A	227;227;226,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	957	959	GGA	243;243;242	G,A;G;A	242,1;243;241	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1041	1043	GGT	266;267;266	G,C;G;T,C	265,1;267;265,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1095	1097	AGC	266;265;264	A;G;C,T	266;265;263,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1161	1161	T	272	T	272	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	1	SNP	p	G120K	0	.	.	358	360	GGT	888	890	GGT	246;245;245	G;G;T	246;245;245	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	1	SNP	p	A121N	0	.	.	361	363	GCC	891	893	GCC	243;243;241	G;C;C	243;243;241	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2916	porB1b	1035	1035	95.73	porB1b.l6.c4.ctg.1	2002	181.3	1	SNP	p	A121D	0	.	.	361	363	GCC	891	893	GCC	243;243;241	G;C;C	243;243;241	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10982	rpoB	4179	4179	100.0	rpoB.l15.c30.ctg.1	5446	251.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2355	2357	AAT	300;300;300	A;A;T	300;300;300	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1572	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1526	128.6	1	SNP	p	V57M	1	.	.	169	171	ATG	787	789	ATG	285;288;290	A;T;G,C	285;288;289,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
